Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Meredith Hay
University of Arizona, Department: Internal Medicine/medicine
Should you be removed from our database? Contact us at [email protected]. Read more below.
ProNeurogen, Inc.
Payment for services (e.g., consulting fees, honoraria, paid authorship)
The financial entity licenses the technology being studied in the research. The research involves intellectual property invented by Dr. Hay and is designed to support new indications or applications of the intellectual property. The activities of the financial entity are related to the subject of the research, and the research results could affect the value of the financial entity. The intellectual property used in the research is the basis of the University of Arizona's application to the U.S. Food and Drug Administration for an investigator-initiated Investigational New Drug. In return for licensing the intellectual property for the study drug to the financial entity, the University of Arizona obtained (b)(4) warrants in the financial entity and (b)(4) royalties on the entity's net sales.
Evaluation of the Safety and Efficacy of Angiotensin 1-7 to Enhance Cognitive Function in Participants Undergoing Coronary Artery Bypass Graft (CABG) Surgery
PROJECT NARRATIVE The surgery to repair coronary blockage or coronary artery bypass graft surgery (CABG) is known to be associated with cognitive impairment and memory loss in humans. While the loss of cognitive function that occurs in CHF and following CABG is recognized clinically, there are no therapies or strategies to prevent or even treat CHF-induced cognitive impairment. The goal of this project is to develop a novel peptide therapeutic to treat cardiovascular disease and CABG-induced cognitive impairment.
Filed on April 17, 2017.
Tell us what you know about Meredith Hay's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Meredith Hay filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Meredith Hay | University of Arizona | Conflict of Interest | ProNeurogen, Inc. | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.